Bayesian Estimation of Mixture Models with Prespecified Elements to Compare Drug Resistance in Treatment-Naïve and Experienced Tuberculosis Cases

PLoS Computational Biology

Volumn 9, Issue 3, 2013, Pages

  Izu, Alane ^a   Cohen, Ted ^b,c   DeGruttola, Victor ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG THERAPY; MIXTURES;

ACQUIRED RESISTANCE; BAYESIAN APPROACHES; BAYESIAN ESTIMATIONS; BRANCHING TREE; COST OF RESISTANCES; DRUG-RESISTANCE; DRUG-RESISTANT STRAINS; FITNESS COSTS; MIXTURE MODELING; MYCOBACTERIUM TUBERCULOSIS;

BAYESIAN NETWORKS;

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; BAYES THEOREM; DRUG RESISTANT TUBERCULOSIS; HUMAN; MATHEMATICAL MODEL; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROBABILITY;

EID: 84875985285     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002973     Document Type: Article

References (18)

1. Desper R, Jiang F, Kallioniemi OP, Moch H, Papadimitriou CH, et al. (1999) Inferring tree models for oncogenesis from comparative genome hybridization data. J Comput Biol 6: 37-51.
2. Beerenwinkel N, Rahnenführer J, Däumer M, Hoffmann D, Kaiser R, et al. (2005) Learning multiple evolutionary pathways from cross-sectional data. J Comput Biol 12: 584-598.
3. Izu A, Cohen T, Mitnick C, Murray M, DeGruttola V, (2011) Bayesian methods for fitting mixture models that characterize branching tree processes: an application to development of resistant TB strains. Stat Med 30: 2708-2720.
4. World Health Organization (2008). Anti-tuberculosis drug resistance in the world: report no. 4. Available: http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf. Accessed 11 April 2012.
5. Gagneux S, Small PM, (2007) Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 7: 328-337.
6. Beerenwinkel N, Rahnenführer J, Kaiser R, Hoffmann D, Selbig J, et al. (2005) Mtreemix: a software package for learning and using mixture models of mutagenetic trees. Bioinformatics 21: 2106-2107.
7. Dye C, Williams BG, Espinal MA, Raviglione MC, (2002) Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295: 2042-2046.
8. World Health Organization European Region (2011). The consolidated action plan to prevent and combat multidrug- and extensively drug resistant tuberculosis in the who European region 2011-2015. Available: http://www.euro.who.int/ data/assets/pdf_file/0007/147832/wd15E TB ActionPlan 111388.pdf. Accessed 11 April 2012.
9. Böttger EC, (2008) Tuberculosis: drug resistance, fitness, and strategies for global control. Eur J Pediatr 167: 141-148.
10. Cohen T, Sommers B, Murray M, (2003) The effect of drug resistance on the fitness of Mycobac- terium tuberculosis. Lancet Infect Dis 3: 13-21.
11. Middlebrook G, Cohn ML, (1953) Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 118: 297-299.
12. World Health Organization (2010). Anti-tuberculosis drug resistance in the world: report no. 4. Available: http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf. Accessed 11 April 2012.
13. Farmer P, Kim JY, (1998) Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus". BMJ 317: 671-674.
14. Bruchfeld J, Aderaye G, Palme IB, Bjorvatn B, Ghebremichael S, et al. (2002) Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates from Ethiopian pulmonary tuberculosis patients with and without human immunodeficiency virus infection. J Clin Microbiol 40: 1636-1643.
15. Lockman S, Sheppard JD, Mwasekaga M, Kenyon TA, Binkin NJ, et al. (2000) DNA fingerprinting of a national sample of Mycobacterium tuberculosis isolates, Botswana, 1995-1996. Int J Tuberc Lung Dis 4: 584-587.
16. Lockman S, Sheppard JD, Braden CR, Mwasekaga MJ, Woodley CL, et al. (2001) Molecular and conventional epidemiology of Mycobacterium tuberculosis in Botswana: a population-based prospective study of 301 pulmonary tuberculosis patients. J Clin Microbiol 39: 1042-1047.
17. Van Rie A, Warren R, Richardson M, Gie RP, Enarson DA, et al. (2000) Classification of drug resistant tuberculosis in an epidemic area. Lancet 356: 22-25.
18. Szabo A, Boucher K, (2002) Estimating an oncogenetic tree when false negatives and positives are present. Math Biosci 176: 219-236.